Resonance Health

Company Overview

Resonance Health develops solutions for the non-invasive assessment of iron, fat and fibrosis in human organs through the quantitative analysis of MRI images, acquired on standard MRI scanners with no additional equipment required.

Resonance Health’s original regulatory-cleared MRI-based analysis service, FerriScan®, was launched in 2005 and has since been used as the reference standard* for non-invasive patient liver iron concentration (or LIC) assessment in clinical practice, largely supplanting liver biopsies. Building on the success with FerriScan®, Resonance Health has expanded its services to include iron measurements in the heart, bone marrow, brain, kidney, pancreas and spleen, and fat measurements in the liver, spleen, and pancreas as well as specialist clinical trial services covering CRO, central reading and laboratory services.

Resonance Health’s products and services have achieved regulatory clearance in the U.S., Europe, UK and Australia, and are widely used for both routine clinical patient diagnosis and in clinical trials as outcome measures or screening tools.

Modalities

*Examples of FerriScan® being used as reference standard:

(1) Pirasteh A, Yuan Q, Wang C, Hernando D, Reeder SB, Pedrosa I, et al. Liver R2 Quantification at 3 Tesla in Patients with Iron Overload – Interim Validation Result. ISMRM. 2017

(2) New study highlights “unsafe” T2* MRI method being used for iron overload assessment in thousands of patients [Internet]. TIF. [cited 2023 Oct 4]. Available from https://thalassaemia.org.cy/news/clinical-news/clinical-alert-new-study-highlights-unsafe-t2-mri-method-being-used-for-iron-overload-assessment-in-thousands-of-patients/